MoonLake Immunotherapeutics

MoonLake Immunotherapeutics(MLTX)

ZUG, Switzerland
Biotechnology
WebsiteLinkedInCareers Page

Focus: Tri-Specific Nanobody

MoonLake Immunotherapeutics is a life sciences company focused on Tri-Specific Nanobody.

Dermatology
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT06994936An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
Phase 1
Phase 2
Clinical Trials (1)
NCT05640245Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Phase 2
Phase 2
Clinical Trials (1)
NCT05322473Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2
Phase 3
Clinical Trials (1)
NCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Phase 3
Phase 3
Clinical Trials (1)
NCT06411899A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
Phase 3
Clinical Trials (1)
NCT07223138A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Phase 3
Phase 3
Clinical Trials (1)
NCT06411379Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
Phase 3
Clinical Trials (1)
NCT06768671An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Phase 3
Phase 3
Clinical Trials (1)
NCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Phase 3
Phase 3
Clinical Trials (1)
NCT07007637A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2024
Portfolio: 10 clinical trials
Top TAs: Dermatology
Publications: 5 in PubMed
SEC Filings: 2 available
Therapeutic Area Focus
Dermatology
5 pipeline
Marketed
Pipeline

Financials (FY2025)

R&D Spend
$32M24%
Net Income
-$36M
Cash
$180M
Source: SEC 10-K Filing